Modified anti-EGFR antibody with reduced immunogenicity

本发明涉及特别是欲施用于人的并尤其用于肿瘤治疗性应用的针对EGF受体(HER1)的抗体。该抗体为经修饰的抗体，其中所述修饰导致了抗体在施用于人受试者后引起免疫反应的趋势降低。本发明尤其涉及对不同形式的抗EGFR抗体425及其片段的修饰，以产生当体内使用时较任一未修饰的对应物而言，基本上没有免疫原性或具有较小免疫原性的Mab425变体。 The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	F.J. CARR, G. CARTER, T. JONES
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	本发明涉及特别是欲施用于人的并尤其用于肿瘤治疗性应用的针对EGF受体(HER1)的抗体。该抗体为经修饰的抗体，其中所述修饰导致了抗体在施用于人受试者后引起免疫反应的趋势降低。本发明尤其涉及对不同形式的抗EGFR抗体425及其片段的修饰，以产生当体内使用时较任一未修饰的对应物而言，基本上没有免疫原性或具有较小免疫原性的Mab425变体。 The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.